Molecular Insight Pharmaceuticals

Cambridge, United States Founded: 1997 • Age: 29 yrs Acquired By Progenics
Radiopharmaceuticals and molecular imaging agents for use in oncology
Request Access

About Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals is a company based in Cambridge (United States) founded in 1997 was acquired by Progenics in January 2013.. Molecular Insight Pharmaceuticals operates in a competitive market with competitors including ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others.

  • Headquarter Cambridge, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Molecular Insight Pharmaceuticals Inc
Operational Areas
Healthcare → Medical Devices & Diagnostics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $1.97 M (USD), Grant

    Aug 11, 2011

  • Investors
    HHS

    & 1 more

  • Employee Count
    Employee Count
  • Acquired by
    Progenics

    (Jan 22, 2013)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Molecular Insight Pharmaceuticals

  • Total Funding
  • Total Rounds 14
  • Last Round Grant — $2.0M
  • First Round

    (01 Aug 2007)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2011 Amount Grant - Molecular Insight Pharmaceuticals Valuation

investors

HHS
Sep, 2010 Amount Grant - Molecular Insight Pharmaceuticals Valuation

investors

HHS
Sep, 2010 Amount Grant - Molecular Insight Pharmaceuticals Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Progenics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Molecular Insight Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Molecular Insight Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Molecular Insight Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
domain founded_year HQ Location
Epigenetic tests for personalized cancer assessment and treatment.
domain founded_year HQ Location
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
domain founded_year HQ Location
Genomic tests for urologic cancers are developed and commercialized.
domain founded_year HQ Location
Diagnostics and therapeutics for neurodegenerative disorders are developed.
domain founded_year HQ Location
Small molecule drugs and imaging agent for GI disorders
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Molecular Insight Pharmaceuticals

Frequently Asked Questions about Molecular Insight Pharmaceuticals

When was Molecular Insight Pharmaceuticals founded?

Molecular Insight Pharmaceuticals was founded in 1997 and raised its 1st funding round 10 years after it was founded.

Where is Molecular Insight Pharmaceuticals located?

Molecular Insight Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

What does Molecular Insight Pharmaceuticals do?

Molecular Insight Pharmaceuticals develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy. As of January 18, 2013, Molecular Insight Pharmaceuticals operates as a subsidiary of Progenics Pharmaceuticals.

Who are the top competitors of Molecular Insight Pharmaceuticals?

Molecular Insight Pharmaceuticals's top competitors include ImaginAb, AC Immune and MDxHealth.

Who are Molecular Insight Pharmaceuticals's investors?

Molecular Insight Pharmaceuticals has 2 investors. Key investors include HHS, and Progenics.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available